Corporate calendar for Neurogene Inc. (NGNE): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | ||
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | ||
| 2026-09-14 | $-0.03 | $261M |
| 2026-09-14 | $1M | |
| 2026-09-14 |
Price
| Price | $34.67 |
| Market Cap | $548M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADCT · ALMS · AUTL · BNTC · FULC · LCTX · OCGN
Explore sector: Healthcare · Biotechnology
More sections of NGNE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks